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The exact mechanisms by which natural 
noncoding variants contribute to autoimmune 
diseases have proven very difficult to dissect. 
We used a knockin (KI) approach to address 
this for the inhibitory receptor FcRIIb, un-
covering novel mechanisms of immune regu-
lation and demonstrating that this method 
provides insights into normal immune func-
tion that conventional genetic manipulation 
models do not.
FcRIIb binds to the Fc portion of IgG 
and negatively regulates immune complex–
mediated signaling, including BCR signaling 
on B cells, on which it is the only Fc receptor 
expressed (Nimmerjahn and Ravetch, 2008; 
Smith and Clatworthy, 2010). The low-affinity 
Fc receptor family is found in a complex in a 
systemic lupus erythematosus (SLE)–associated 
region on chromosome 1 in both humans and 
mice (Vyse et al., 1997; Morel et al., 2001; 
Bolland et al., 2002), and dysregulation of 
FcRIIb expression and function has been 
associated with autoimmunity in both species. 
In humans, a single nucleotide polymorphism 
(SNP) in FCGR2B results in reduced inhibitory 
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Genetic variants of the inhibitory Fc receptor FcRIIb have been associated with systemic 
lupus erythematosus in humans and mice. The mechanism by which Fcgr2b variants con-
tribute to the development of autoimmunity is unknown and was investigated by knocking 
in the most commonly conserved wild mouse Fcgr2b promoter haplotype, also associated 
with autoimmune-prone mouse strains, into the C57BL/6 background. We found that in 
the absence of an AP-1–binding site in its promoter, FcRIIb failed to be up-regulated on 
activated and germinal center (GC) B cells. This resulted in enhanced GC responses, in-
creased affinity maturation, and autoantibody production. Accordingly, in the absence of 
FcRIIb activation–induced up-regulation, mice developed more severe collagen-induced 
arthritis and spontaneous glomerular immune complex deposition. Our data highlight how 
natural variation in Fcgr2b drives the development of autoimmune disease. They also show 
how the study of such variants using a knockin approach can provide insight into immune 
mechanisms not possible using conventional genetic manipulation, in this case demonstrat-
ing an unexpected critical role for the activation-induced up-regulation of FcRIIb in 
controlling affinity maturation, autoantibody production, and autoimmunity.
© 2012 Espéli et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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variant found in wild mice and in autoimmune strains is asso-
ciated with an impaired up-regulation of FcRIIb on GC 
B cells, as the result of differential binding of the activation-
induced transcription factor complex AP-1. This stage-specific 
change in FcRIIb expression was associated with enhanced 
GC formation and affinity maturation, but also with the 
spontaneous production of autoantibodies and autoreactive 
memory B cells and with enhanced severity of collagen-
induced arthritis. These data highlight a previously uncharac-
terized role for FcRIIb up-regulation in the control of the 
survival, selection, and affinity maturation of GC B cells.
RESULTS
Conservation of autoimmunity-associated polymorphisms  
in Fcgr2b in wild mice
Genetic variation found in the regulatory regions of Fcgr2b in 
inbred mice (Luan et al., 1996; Jiang et al., 2000; Pritchard et al., 
2000) results in three distinct haplotypes (Fig. 1 A). We con-
firmed that these were the only haplotypes present by sequenc-
ing and examined their distribution within inbred strains using 
the genealogy generated by Beck et al. (2000; Fig. 1 B). Haplo-
type III (which lacks all deletions) was found in the majority of 
commonly used strains such as BALB/c and C57BL/6. Haplo-
type II (comprised of deletions 3 and 4) was found only in 
NZW, SJL/J, and SWR/J mice. Haplotype I (which includes 
deletions 1–3) was found in many autoimmune-prone strains 
such as NZB, NOD, and MRL/MpJ and sometimes appeared 
to arise at points of the inbred mouse genealogy where strains 
had been introduced from external sources (Fig. 1 B).
This observation prompted us to examine genetic variation 
in Fcgr2b in wild mice. Most of the Mus musculus subspecies 
tested were found to be of haplotype I. The few wild mice bear-
ing haplotype III were mainly found in Mus musculus molossinus 
in Japan, which made important genetic contributions to inbred 
strains (Fig. 1 C; Beck et al., 2000; Guénet and Bonhomme, 
2003). The predominance of the autoimmunity-associated hap-
lotype I in the wild suggests it might be under selection pressure 
by infection in a manner analogous to the MHC and KIR loci 
(Espeli et al., 2010) and to FcRIIb in humans (Willcocks et al., 
2010) and thus may be functionally significant.
Naturally occurring variants of Fcgr2b abrogate  
the activation-induced up-regulation of FcRIIb
Because haplotype I is the most commonly observed variant 
in wild mice, is found in SLE-associated loci in NZB and 
MRL/MpJ mice, and may be associated with altered expres-
sion of FcRIIb in B cells and macrophages (Pritchard et al., 
2000), we decided to examine its functional implications 
using a KI approach. We generated a mouse model in which 
the promoter and the first three exons of Fcgr2b from a hap-
lotype I (H1) mouse were knocked in to a C57BL/6 ES cell 
(FcRIIbwild/H1 KI mouse; Fig. 2 A).
The FcRIIbwild/H1 KI mice were viable, bred normally, 
and had no abnormalities in hematopoietic cell numbers 
(not depicted). FcRIIb expression was assessed before 
and after immunization with 4-hydroxy-3-nitrophenylacetyl 
function (Floto et al., 2005; Kono et al., 2005) and has been 
associated with SLE (Kyogoku et al., 2002; Siriboonrit et al., 
2003; Chu et al., 2004; Willcocks et al., 2010) but protection 
against malaria (Clatworthy et al., 2007; Willcocks et al., 
2010), an effect independent of variation in neighboring 
FcRs (Niederer et al., 2010). More recently Baerenwaldt 
et al. (2011) showed using humanized mice that this poly-
morphism affects human B cell development and is associated 
with autoantibody production in vivo. Naturally occurring 
variations have also been described in the promoter of human 
FCGR2B, and these too may be implicated in SLE predispo-
sition (Su et al., 2004; Blank et al., 2005). Consistent with 
human data, FcRIIb-deficient mice have an enhanced im-
mune response (Takai et al., 1996), are prone to inducible 
(Yuasa et al., 1999) and spontaneous (Bolland and Ravetch, 
2000) autoimmunity, and have an increased frequency of po-
tentially autoreactive B cell clones in their germinal centers 
(GCs; Tiller et al., 2010). In addition, FcRIIb balances the 
risk of pneumococcal bacteremia with that of septic shock 
(Clatworthy and Smith, 2004) and determines the outcome 
of malarial infection (Clatworthy et al., 2007). The original 
KO mouse was generated using a 129/Sv embryonic stem 
(ES) cell, and the presence of polymorphisms in genes neigh-
boring Fcgr2b in this strain may account for part of its pheno-
type (Bygrave et al., 2004). The specific effect of FcRIIb in 
SLE pathogenesis in MRL/Lpr mice has been confirmed, 
however, by lentiviral (McGaha et al., 2005) and cell-specific 
transgenic approaches (Brownlie et al., 2008). More recently, 
the careful analysis of FcRIIb-deficient mice made on the 
C57BL/6 background was consistent with FcRIIb contrib-
uting to SLE in a polygenic fashion (Boross et al., 2011). 
Variation in demethylated regions of the Fcgr2b promoter and 
intron 3 was described in several autoimmune-prone mouse 
strains, including NOD, NZB, NZW, and 129/Sv (Luan 
et al., 1996; Jiang et al., 2000; Pritchard et al., 2000), in which 
it was associated with reduced FcRIIb expression and 
inhibitory function (Pritchard et al., 2000). Analyses of 
congenic strains have shown that mice bearing the SLE sus-
ceptibility loci Sle1 or Nba2 (derived from the NZW and 
NZB strains, respectively) show reduced FcRIIb expression 
on GC B cells and plasma cells (PCs; Rahman and Manser, 
2005; Lin et al., 2006; Vuyyuru et al., 2009; Jrgensen et al., 
2010) and enhanced B cell immune responses (Vuyyuru 
et al., 2009; Jrgensen et al., 2010). However, these con-
genic strains carry large regions of chromosome 1 of NZB or 
NZW origin encompassing many genes involved in the con-
trol of the immune response, and thus Fcgr2b variants cannot 
be conclusively implicated in the phenotype observed in 
them. Moreover, the mechanism by which natural Fcgr2b 
variation contributes to autoimmunity in mouse and human is 
not known. Studies of natural genetic variants of Fcgr2b might 
allow dissection of these mechanisms in a way that models 
involving absolute deficiency, constitutive overexpression, 
or large congenic regions may not.
After analyzing the variants of Fcgr2b present in wild mice, 
we used a KI approach to show that a naturally occurring 
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Figure 1. Conservation of naturally occurring polymor-
phisms in Fcgr2b in congenic and wild mice. (A) Four dele-
tions (X) have been identified within regulatory regions of the 
murine Fcgr2b gene, two in the promoter and two in intron 3. 
These deletions form three haplotypes in inbred strains of mice. 
The core promoters of Fcgr2b from the NZB (haplotype I), NZW 
(haplotype II), and C57BL/6 (haplotype III) strains were aligned 
using ClustalW. Polymorphisms present only in the NZW strain 
are highlighted in purple, those present only in the NZB strain in 
green, and those present in both NZB and NZW in yellow. A pre-
dicted AP-1–binding site is indicated by a red box. The asterisks 
below the sequences represent sequence identity. (B) Distribution 
of Fcgr2b polymorphisms within the inbred strain genealogy gen-
erated by Beck et al. (2000). (C) Fcgr2b haplotypes in wild mice. 
53 DNA samples were obtained from wild mice from around the 
world, and the Fcgr2b haplotype was determined. Each circle rep-
resents a separate DNA sample.
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splenic and BM PCs, in contrast to the reduction previously 
noted in NZB (Xiang et al., 2007) and Sle1.B6 congenic 
(Jrgensen et al., 2010) PCs (Fig. 2, D and G).
FcRIIb expression was also normal on all myeloid sub-
populations tested (splenic dendritic cells, monocytes, and 
conjugated to KLH (NP-KLH) in alum. FcRIIb expres-
sion was identical on naive B cells (B220+PNA), but the 
increase in FcRIIb expression observed on control GC 
B cells was not seen in FcRIIbwild/H1 mice (Fig. 2 B). FcRIIb 
expression was normal on memory B cells (Fig. 2 C) and on 
Figure 2. Defective up-regulation of 
FcRIIb expression on GC B cells in 
FcRIIBwild/H1 KI mice. (A) Cloning strategy 
for the generation of the FcRIIBwild/H1 KI 
mice. A PCR product corresponding to the 
promoter and three first exons from Fcgr2b 
from haplotype I (1,271 bp) was first fused 
with the 5 homology arm (1,996 bp from 
haplotype III). The fusion product was then 
cloned into the targeting vector (pCR_LPacI-
Neo; Ozgene). The 3 homology arm (3,905 bp 
from haplotype III) was then amplified and 
cloned in the targeting vector. (B–G) Surface 
expression of FcRIIb was assessed by flow 
cytometry 14 d after NP-KLH immunization 
on naive (PNAB220+) and GC B cells 
(PNA+B220+; B), memory B cells (IgG1+/
PNACD38+; C), splenic PCs (CD138+B220lo; D), 
and BM PCs (CD138+B220lo; G). Surface 
FcRIIb expression was also assessed by flow 
cytometry on unimmunized mice for splenic 
follicular B cells (CD21+CD23+), marginal zone 
B cells (CD21+CD23lo), and transitional B cells 
(CD21loCD23lo; E) and for BM pre-B cells 
(IgMB220+), immature B cells (IgM+B220+), 
and recirculating mature B cells (IgMhiB220+; F). 
(left) Representative dot plot of the gating 
strategy used to determine FcRIIb expression 
on each subset. (middle) Representative over-
lay of FcRIIb expression by FcRIIbwild/H1 KI, 
WT, and FcRIIb KO mice is shown for 
PNA+B220+ GC B cells. (right) Geometric mean 
fluorescence intensity (MFI) of FcRIIb expres-
sion on the different cell subsets. (H) Spleno-
cytes were stimulated with 20 µg/ml goat 
anti–mouse IgM F(ab)2 or intact goat anti–
mouse IgM for 72 h at 37°C. The expression 
of FcRIIb on activated B cells was assessed 
by flow cytometry. The mean fluorescence 
intensity of FcRIIb on activated B cells was 
plotted for WT and FcRIIbwild/H1 KI mice. For 
all experiments, n ≥ 4 mice per group, and 
data are representative of at least three in-
dependent experiments. Error bars represent 
SEM, and p-values were determined using 
the Mann–Whitney two-tailed test with a 
risk of 5% (*, P < 0.05; **, P < 0.01).
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Transcriptional control of FcRIIb up-regulation
The effect of Fcgr2b promoter variants on transcription was 
analyzed by luciferase assay. The polymorphisms present in the 
Fcgr2b promoter in haplotypes I (NZB, KI) and II (NZW) 
were associated with lower transcriptional activity compared 
with the control haplotype III (C57BL/6) promoter after 
B cell activation (Fig. 3 A). Consistent with the equivalent 
effects of haplotypes I and II in reducing Fcgr2b transcriptional 
activity, congenic mice incorporating distal chromosome 1 
from either NZB or NZW backgrounds demonstrate reduced 
FcRIIb expression on GC B cells (Fig. 3 A; Xiu et al., 2002; 
Rahman et al., 2007). As this suggests that the genetic variants 
driving the failure of activation-induced up-regulation are 
neutrophils), on follicular dendritic cells, on resting follicular 
and marginal zone splenic B cells, and on BM mature recir-
culating B cells (Fig. 2, E and F; and not depicted). In addi-
tion to the changes seen on GC B cells, FcRIIb expression 
was also lower on FcRIIbwild/H1 KI splenic transitional B cells 
and BM pre-B cells (Fig. 2, E and F). After in vitro stimula-
tion, expression of FcRIIb was reduced on splenic B cells 
from FcRIIbwild/H1 KI compared with controls, suggesting 
that it is the activation-induced up-regulation of FcRIIb 
which is abnormal in these mice (Fig. 2 H). Thus, naturally 
occurring variants in the Fcgr2b promoter abrogate activation-
induced up-regulation of FcRIIb, an effect most promi-
nently seen on GC B cells.
Figure 3. The reduced transcriptional activity of the haplotype I Fcgr2b promoter is caused by three single nucleotide substitutions leading to 
defective AP-1 binding. (A) The transcriptional activity of the WT, KI, NZB, and NZW promoter of Fcgr2b was determined in the Bal17 B cell line stimulated 
with LPS for 48 h. WT versus: KI, P = 0.015; NZW, P = 0.037; and NZB, P = 0.034. (B) The transcriptional activity of the WT promoter mutated at the indicated 
positions was determined as in A. WT versus: KI/NZB, P = 0.02; WT GG1/+2AA, P = 0.1; WT GG1/+2AA/T161C, P = 0.38; WT GG1/+2AA/G79C, P = 0.0025; WT 
GG1/+2AA/C59T, P = 0.88; WT GG1/+2AA/A19C, P = 0.5; and WT G79C, P = 0.3. (C) The transcriptional activity of the KI/NZB promoter mutated at the indi-
cated positions was determined as in A. WT versus: KI/NZB, P = 0.001; KI/NZB AA1/+2GG/C79G, P = 0.07; KI/NZB C79G, P = 0.02; and KI/NZB AA1/+2GG,  
P = 0.94. KI/NZB versus: KI/NZB AA1/+2GG/C79G, P = 0.03; KI/NZB C79G, P = 0.06; and KI/NZB AA1/+2GG, P = 0.001. (B and C) The dashed lines represent the 
luciferase activity of the Fcgr2b KI promoter. (D) Bal17 cells were stimulated for 24 h with anti-Ig or LPS before ChIP with anti–c-Fos or –c-Jun or an isotype 
control. The region of the Fcgr2b promoter encompassing position 79 was amplified by PCR from input and coimmunoprecipitated DNA. (E) WT and 
FcRIIbwild/H1 KI splenic CD19+ B cells were stimulated for 8 h with anti-Ig or LPS and processed as in D. The region of the Fcgr2b promoter encompassing 
position 79 was amplified by SYBR green quantitative PCR, and the CT of isotype and c-Fos or c-Jun was plotted for each condition. In all panels, error 
bars represent SEM, and p-values were determined using the Mann–Whitney two-tailed test with a risk of 5%.
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We confirmed that after activation, AP-1 binds to the Fcgr2b 
promoter at position 79 by performing c-Fos and c-Jun chro-
matin immunoprecipitation (ChIP) on a B cell line of haplotype 
III (Fig. 3 D). In primary B cells, the binding of c-Fos and c-Jun 
to position 79 of Fcgr2b promoter was up-regulated on 
C57BL/6 B cells after stimulation, but no binding was detected 
for either c-Fos or c-Jun in resting and activated FcRIIbwild/H1 
KI B cells (Fig. 3 E). These results suggest that AP-1 drives the 
activation-induced up-regulation of FcRIIb and that natural 
variants of the Fcgr2b promoter disrupt this process.
FcRIIb up-regulation controls GC B cell number  
and affinity maturation
Reduced expression of FcRIIb would be expected to en-
hance BCR-mediated signaling and the phosphorylation 
of downstream kinases. After immunization and ex vivo 
stimulation, both phospho-BLNK and phospho-Syk were 
increased in FcRIIbwild/H1 KI GC B cells compared with 
naive B cells (Fig. 4 A), consistent with the lower expression 
common to both NZB and NZW strains, we focused on the 
seven SNPs found in both of these strains but not in C57BL/6 
(Fig. 1 A). None of the individual polymorphisms significantly 
reduced the transcriptional activity of Fcgr2b promoter when 
mutated alone, but the combination of the GG1/+2AA and 
G79C SNPs reduced the transcriptional activity to a level 
similar to that of the KI/NZB promoter (Fig. 3 B). When 
these variants were corrected in the NZB promoter, expres-
sion was restored to the C57BL/6 level (Fig. 3 C). These re-
sults suggest that these two substitutions are sufficient to 
disrupt the activation-induced up-regulation of FcRIIb. 
Several transcription factor binding site prediction algorithms 
(see Materials and methods for details) predicted the existence 
of an AP-1–binding site overlapping with position 79 of the 
Fcgr2b promoter from haplotype III (C57BL/6) but not from 
haplotypes I or II (NZB/KI and NZW; Fig. 1 A, red box). 
AP-1 is a heterodimer composed of the transactivators c-Fos 
and c-Jun, and its expression is induced by BCR or TLR 
cross-linking on B cells (Yi et al., 2003; de Gorter et al., 2007). 
Figure 4. Increased GC reaction in 
FcRIIbwild/H1 KI mice. (A) 8 d after immuni-
zation with NP-KLH in alum, splenocytes were 
stimulated ex vivo, and the mean fluorescence 
intensity (MFI) of phospho-Syk and phospho-
BLNK in GC B cells gated as B220+/GL7hiFAShi 
and naive B cells gated as B220+/GL7FAS 
was determined by flow cytometry. The ratio 
of naive and GC B cell mean fluorescence 
intensity is plotted. Data are representative of 
two or three independent experiments de-
pending on the time points. n = 4 mice per 
group. (B) Splenic GC B cell numbers were 
determined by flow cytometry at day 8. Rep-
resentative dot plots of WT and KI are shown. 
(C) GC formation in the spleen 8 d after im-
munization was assessed by immunohistol-
ogy. Staining: anti-B220, B cell follicle; 
anti-CD8, T cell zone; and anti-KI67, GCs. 
Representative images of at least four mice 
per group are shown. Bars, 50 µm. (D and E) 
GC B cells (D) and NP-specific GC B cells  
(E) were enumerated at days 7, 8, 10, and 11 
after immunization. n ≥ 4 mice, and data are 
representative of at least two experiments per 
time point. (F) 8 d after immunization, apop-
tosis and proliferation of GC B cells were  
assessed by staining apoptotic cells with 
CaspGLOW (left) and cells in cycle with anti-
KI67 (right). n = 4 mice for the KI and 5 mice 
for the WT. Data are representative of at least 
two independent experiments. (G) The number 
of TFH cells (CD4+/CXCR5hiPD1hi) per spleen 
was determined 11 d after immunization with 
NP-KLH in alum. n = 6 for the WT and 5 for 
the KI. Data are representative of three inde-
pendent experiments. In all panels, error bars 
represent SEM, and p-values were determined 
using the Mann–Whitney two-tailed test with 
a risk of 5%.
JEM Vol. 209, No. 12 
Article
2313
NP-specific GC B cells from FcRIIbwild/H1 KI mice had a 
similar number of mutations per V gene as controls, but 
56.4% bore the high-affinity mutation W33L versus 37% in 
controls (Fig. 6, D and E).
B cell–deficient µMT mice were reconstituted with 
FcRIIbwild/H1 KI or control BM. The FcRIIbwild/H1 KI B cell–
specific chimeras showed reduction in FcRIIb expression 
on GC B cells and increased GC B cell number compared 
with WT chimeras (not depicted). They also had a higher 
anti-NP2/NP12 serum IgG1 ratio compared with controls 
(Fig. 6 F) and enhanced accumulation of the high-affinity 
W33L mutation in VH186.2 sequences from sorted single 
NP-specific GC B cells (13.3% in FcRIIbwild/H1 KI vs. 7% in 
control chimeras; Fig. 6 G), demonstrating that the increased 
affinity maturation observed in FcRIIbwild/H1 KI mice is 
B cell intrinsic and further demonstrating that FcRIIb ex-
pression on GC B cells plays an important role in controlling 
affinity maturation and selection in the GC.
FcRIIb up-regulation alone can control the development  
of autoreactive antibodies and memory after immunization
Control of the GC reaction has long been proposed to consti-
tute a crucial checkpoint preventing the breakdown of immune 
tolerance (Goodnow et al., 2005). As total GC B cells, but not 
those specific for NP, were increased in FcRIIbwild/H1 KI mice, 
we wondered whether immunization might lead to the by-
stander activation of autoreactive clones in these mice, a pheno-
menon observed after viral or bacterial infection in humans 
and mice (Zinkernagel et al., 1990; Brás and Aguas, 1995; 
Hunziker et al., 2003). 8 d after NP-KLH immunization, higher 
titers of antichromatin and anti–double-stranded DNA (dsDNA) 
IgM and IgG1 were observed in FcRIIbwild/H1 KI mice. These 
autoreactive antibodies were not detectable 11 d after immuni-
zation, consistent with a transient production of short-lived 
autoreactive PCs. After a secondary immunization, however, a 
more substantial increase in antichromatin and anti-dsDNA an-
tibodies was seen (Fig. 7 A), suggesting that autoreactive B cell 
of FcRIIb on GC B cells reducing the BCR activation 
threshold of these cells. As early as 7 d after immunization, an 
increase in the number of total GC B cells in FcRIIbwild/H1 
KI mice was observed by flow cytometry and immunohis-
tochemistry and found to hold true throughout the 
GC response (Fig. 4, B–D). Surprisingly, no difference was 
observed in the number of NP-specific GC B cells (Fig. 4 E). 
We found that half as many FcRIIbwild/H1 KI GC B cells 
contained active caspases (as determined by CaspGLOW 
staining; Fig. 4 F) and were TUNEL positive (not depicted) 
compared with controls, consistent with reduced apopto-
sis, whereas similar proportions were in cell cycle as deter-
mined by KI67 expression (Fig. 4 E). Interestingly, despite 
clear evidence of increased GC number, the number of 
T follicular helper cells (TFH cells) was normal (Fig. 4 G). These 
results suggest that in the absence of FcRIIb up-regulation, 
the BCR activation threshold is decreased, leading to 
enhanced signaling and survival of GC B cells.
This dysregulation of the GC led us to examine antibody 
production, selection, and affinity maturation. FcRIIbwild/H1 
KI mice had an increase in the titer of NP-specific IgM and 
IgG1 that was particularly prominent early after immuniza-
tion, and the increased number of NP-specific IgM and IgG1 
secreting cells in the spleen and BM was consistent with this 
(Fig. 5, A–C). T-independent type 2 immune responses to 
NP-Ficoll also showed a modest increase in NP-specific IgM 
and IgG3 early after immunization (Fig. 5, D and E). Although 
total anti-NP IgG1 was only significantly raised in the first 
week after NP-KLH immunization (Figs. 5 and 6 A), the 
titer of high-affinity NP2-specific IgG1 was higher in the KI 
mice at all time points analyzed (Fig. 6 B). Consistent with 
this, the NP2/NP12 ratio was higher in FcRIIbwild/H1 KI 
mice from day 14, indicating enhanced affinity maturation 
(Fig. 6 C). To confirm this, we performed single cell sorting 
of NP-specific IgG1+ GC B cells. We sequenced the Ig heavy 
chain VH186.2, which is preferentially used by clones specific 
for NP, and analyzed somatic hypermutation (Smith et al., 1997). 
Figure 5. The early immune response is 
increased in FcRIIbwild/H1 KI mice. (A) NP-
specific IgM and IgG1 antibody serum titers 
were determined by ELISA 6 and 8 d after 
immunization with NP-KLH. (B) NP-specific 
IgM and IgG1 AFCs were enumerated by 
ELISPOT at day 8 in the spleen. Data are repre-
sentative of at least two independent experi-
ments. (C) NP-specific IgG1 AFCs were 
enumerated by ELISPOT at day 11 in the 
spleen and the BM. Two experiments have 
been pooled. (D) NP-specific IgM and IgG3 
antibody serum titers were determined by 
ELISA 2, 6, and 12 d after immunization with 
NP-Ficoll. (E) Splenic NP-specific IgG3 and 
IgM AFCs were enumerated by ELISPOT 12 d 
after immunization. In all panels, error bars 
represent SEM, and p-values were determined 
using the Mann–Whitney two-tailed test with 
a risk of 5%. RU, relative units.
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are restrained by the genetic complexity inherent to an out-
bred population and by the fact that limited experimental 
manipulation of the immune response is possible. Absolute 
deficiencies or overexpression models do not replicate the 
complex and potentially subtle effects on gene regulation that 
common natural variants might confer. Congenic approaches 
are also rarely able to prove associations, as they invariably 
contain genetic material that extends beyond the immediate 
regions of interest. We have used a mouse KI approach to 
overcome these limitations and study the impact of genetic 
variation in Fcgr2b promoter on immune regulation. This has 
revealed the potential importance of subtle regulatory varia-
tions seen in wild mouse populations and in doing so has 
provided novel insight into GC regulation by the inhibitory 
receptor FcRIIb.
The Fcgr2b promoter variant found in most wild mice and 
in several autoimmune-prone strains was associated with a 
failure of B cells to up-regulate expression of FcRIIb upon 
activation. This increase in FcRIIb expression upon activa-
tion has been noted before (Rudge et al., 2002), but its regula-
tion and functional significance were unknown. This promoter 
variant was not associated with FcRIIb expression changes 
previously described on myeloid-derived cells (Pritchard et al., 
2000) or PCs (Xiang et al., 2007; Jrgensen et al., 2010) from 
NZB or NZW mice, suggesting the latter are governed by 
memory was generated during the primary immunization in 
FcRIIbwild/H1 KI mice. Given the dysregulation apparent in 
FcRIIbwild/H1 KI mice, we examined predisposition to sponta-
neous autoantibody production in these mice. By 14 mo of age, 
FcRIIbwild/H1 KI mice produced significantly more antichro-
matin and anti-dsDNA autoantibodies than sex- and age-
matched control littermates (Fig. 7 B), and females had 
evidence of pronounced glomerular immune complex deposi-
tion (Fig. 7 C), although they had no evidence of proteinuria 
nor impairment of kidney function (not depicted).
This production of switched autoantibodies in response 
to immunization and the spontaneous development of auto-
antibodies with age suggest a breakdown in tolerance that 
could predispose to immune-mediated disease. This was tested 
in the collagen-induced arthritis model. Arthritis developed 
in 75% of both genotypes, but this incidence was reached in 
6 d in FcRIIbwild/H1 KI mice against 14 d in controls. The 
severity of the disease was also increased in the FcRIIbwild/H1 
KI mice (Fig. 7 D), further supporting a role for naturally oc-
curring polymorphisms of Fcgr2b in increasing susceptibility 
to autoimmune disease.
DISCUSSION
Analysis of the effect of naturally occurring polymorphisms 
on the immune response has proven difficult. Human studies 
Figure 6. B cell–specific increased affinity mat-
uration in FcRIIbwild/H1 KI mice. (A and B) Total 
NP12-specific IgG1 antibody titer (A) and high-affinity 
NP2-specific IgG1 antibody titer (B) were determined 
by ELISA 7, 14, 21, and 28 d after immunization with 
NP-KLH and 7 d after secondary immunization (day 35). 
Concentrations are expressed in relative units  
(RU). (C) The ratio of high-affinity anti-NP2 and total 
anti-NP12 IgG1 titer at each time point was deter-
mined. n = 8 mice per group, and data are represen-
tative of at least two independent experiments. (D) VH 
mutation analysis of single cell sorted NP-specific GC 
B cells 11 d after immunization with NP-KLH (three 
pooled mice for each group). n = 54 sequences for 
the WT, and n = 62 sequences for the KI mice. Data 
are representative of three independent experiments. 
(E) The frequency of the high-affinity mutation W33L 
in VH186.2 CDR1 was assessed after nested PCR and 
sequencing. (F) WT and FcRIIbwild/H1 KI µMT chimera 
mice were immunized with NP-KLH, and NP2/NP12 
IgG1 ratio was determined by ELISA after 11 d. n = 12 
mice for the WT, and n = 14 mice for the KI from 
three experiments pooled. (G) µMT chimera were 
immunized with NP-KLH, and GC B cells were sorted 
11 d later from three pooled WT and three pooled KI 
chimera mice. The frequency of the high-affinity 
mutation W33L in VH186.2 CDR1 was assessed after 
nested PCR and sequencing of each clone. n = 56 
sequences for the WT, and n = 60 sequences for the 
KI chimera mice. Data are representative of two inde-
pendent experiments. In all panels, error bars repre-
sent SEM, and p-values were determined using the 
Mann–Whitney two-tailed test with a risk of 5%.
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and SHP-1 (Khalil et al., 2012), which are under the control of 
several inhibitory receptors, including FcRIIb. Accordingly, 
we observed an enhanced early GC reaction and humoral im-
mune response in the absence of FcRIIb up-regulation. Sur-
prisingly, however, we observed an early and sustained increase 
in affinity maturation of antigen-specific GC B cells in these 
mice. Previous models suggested that reduction of the BCR 
activation threshold might, on the contrary, result in less strin-
gent selection of B cells on the basis of affinity, and thus less 
affinity maturation (Tarlinton and Smith, 2000). Our results 
allow us to propose a model explaining this unexpected find-
ing. The FcRIIbwild/H1 KI mice display reduced apoptosis and 
increased number of total GC B cells but normal antigen-
specific GC B and TFH cell numbers compared with WT mice, 
suggesting that FcRIIb up-regulation limits the survival of 
antigen nonspecific (or bystander) GC B cells. Competition 
for TFH help has been shown to be a limiting factor for B cell 
affinity maturation (Schwickert et al., 2011), and it is therefore 
possible that competition between NP-specific B cells and 
non-NP B cells for limited TFH help is responsible for the in-
creased affinity maturation seen in FcRIIbwild/H1 KI mice. 
This could constitute a new model for selection in the GC, 
where B cell activation threshold controls survival of bystander 
B cells, whereas affinity maturation of antigen-specific B cells 
is controlled by competition for TFH and/or antigen.
genetic variation not included in the FcRIIbwild/H1 KI mice, 
but likely in either intron 3 or more distantly. Our results 
have revealed that this increased expression on GC B cells is 
likely to be driven by the transcription factor AP-1, itself in-
duced by activation through the BCR or TLRs (Yi et al., 
2003; de Gorter et al., 2007). It is interesting to note that 
AP-1 also binds to the human FCGR2B promoter (Blank et al., 
2005; Olferiev et al., 2007). The FCGR2B promoter haplo-
type 2B4, for which an association with SLE has been pro-
posed, is also associated with reduced binding of AP-1 and 
lower expression of FcRIIB on activated cells (Blank et al., 
2005; Olferiev et al., 2007). This suggests that natural variants 
affecting the same pathway may have been conserved in both 
human and mouse. Moreover, AP-1 is predicted to bind to 
the promoters of several other inhibitory receptors such as 
CD22 (Andersson et al., 1996), PIR-B (Alley et al., 1998), and 
CD72 (unpublished data). Activation-induced expression of 
inhibitory receptors may thus represent an important general 
mechanism of immune regulation.
This failed up-regulation of FcRIIb expression on GC 
B cells has a significant impact on the immune response. Lower 
FcRIIb expression was associated with a reduced BCR acti-
vation threshold on GC B cells. This result fits with a recent 
study showing that GC B cell BCR signaling is dampened by 
increased expression and activation of the phosphatases SHIP-1 
Figure 7. FcRIIbwild/H1 KI mice demonstrate 
increased autoantibody production and are 
more susceptible to collagen-induced arthri-
tis. (A) After immunization with NP-KLH, anti-
chromatin (top) and anti-dsDNA (bottom) IgM 
and IgG1 titers were determined in WT and 
FcRIIbwild/H1 KI mice at days 8 and 11 and 7 d 
after secondary immunization. n ≥ 4. Data are 
representative of at least two independent experi-
ments. (B) Antichromatin IgG titer was deter-
mined in sex- and age-matched mice between 11 
and 18 mo old. n = 6 mice for the WT, and n = 8 
mice for the FcRIIbwild/H1 KI. (C) IgG and IgM 
immune complex deposition in the kidney glom-
eruli of ageing mice was determined by immuno-
histofluorescence and quantified using Volocity. 
The relative intensity was normalized to the size 
of the glomeruli. The results obtained from two 
different ageing cohorts have been pooled. Mice 
were all between 14.5 and 15.5 mo old at time of 
sacrifice. (D) Representative incidence of arthritis 
after collagen injection (left). Disease severity in 
mice developing arthritis was scored from 1–3 
per paw for a total of 1–12 per animal (right).  
Day 0 corresponds to the onset of disease. Data 
from three independent experiments were pooled. 
In all panels, error bars represent SEM, and p-values 
were determined using the Mann–Whitney two-
tailed test with a risk of 5%, with the exception of 
D (right), in which the p-value was determined 
using the Kruskal–Wallis test. RU, relative units.
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The product was reamplified with primers mGRII53(349) and mGRII35(22) 
for 20 cycles. Sequencing was performed using mGRII53(349) and 
mGRII35(22) as primers with the Big Dye terminator sequencing kit (Perkin-
Elmer) according to the manufacturer’s instructions and analyzed on an ABI 
Prism 377 automatic DNA sequencer (Applied Biosystems). Primers were 
purchased from Oswel and are detailed in Table S1.
Flow cytometry. Single cell suspensions of spleen and BM were prepared 
as previously described (Espeli et al., 2011). For phosphoflow staining, 
splenocytes from mice immunized with NP-KLH were stimulated at 37°C 
for 5 or 10 min with 10 µg/ml of a goat anti–mouse IgG (H+L) antibody 
(Jackson ImmunoResearch Laboratories, Inc.). Cells were then fixed with 
ice-cold methanol on ice for 30 min before staining with the relevant anti-
bodies. Staining was performed with the antibodies and molecules described 
in Table S2. FACS analysis was performed on a Cyan analyzer (Dako) or a 
Fortessa II (BD), and data were analyzed with FlowJo software (Tree Star).
Luciferase assay and mutagenesis. The promoter region and the 5 un-
translated region of Fcgr2b (from position 907 to 586) were amplified from 
WT (C57BL/6), FcRIIBwild/H1 KI, NZB, and NZW genomic DNA and 
cloned into the pGL4.14 hLuc vector (Promega). The list of the different 
primers used is provided in Table S1. The Fcgr2b WT and KI constructs 
were mutated using the QuikChange mutagenesis kit (Agilent Technolo-
gies) and the indicated primers (Table S1).
Bal17 cells (mature B cell line from BALB/c origin, haplotype III) were 
stimulated with 10 µg/ml LPS and transiently transfected with the different 
pGL4.14 hLuc vectors (Promega) and a pCMV Renilla vector (gift of 
N. Lapaque and T. de Wouter [Institut Micalis, Jouy-en-Josas, France]) as a 
normalization vector using Lipofectamine 2000 (Invitrogen). Luciferase and 
Renilla activity were analyzed after 24 h using the Dual-glo kit (Promega) 
and a Glomax reader (Promega). Relative luciferase activity was calculated 
by normalizing the luciferase to the Renilla OD.
Transcription factor binding site predictions. The 40 residues sur-
rounding position 1/+2 and the 36 residues surrounding position 79 
from WT and FcRIIbwild/H1 KI mice were analyzed for differential tran-
scription factor binding sites with the JASPAR database and the TRANS-
FAC 6.0–based algorithms TFsearch, Patch, and MATCH. JASPAR, TFsearch, 
and Patch predicted the existence of an AP-1–binding site in the WT se-
quence only. Only MATCH predicted the existence of an AP-1–binding 
site in both the WT and KI sequences.
ChIP. Bal17 cells or MACS-purified CD19+ splenic B cells were left un-
treated or stimulated for the indicated period with 10 µg/ml goat anti–mouse 
IgG (H+L; Jackson ImmunoResearch Laboratories, Inc.) or with 10 µg/ml 
LPS (Sigma-Aldrich). ChIP was performed with the ChIP kit from Abcam 
and the anti–c-Jun (H-79) and anti–c-Fos (K-25) antibodies from Santa 
Cruz Biotechnology, Inc. A rabbit anti–mouse IgG (Cell Signaling Technol-
ogy) was used as an isotype control. Total chromatin (input) and the immuno-
precipitated chromatin were used as template, and the 79 locus of the 
Fcgr2b promoter was amplified by conventional or quantitative PCR using 
the primers indicated in Table S1. Quantitative PCR was performed with 
the QuantiFast SYBR green PCR kit (QIAGEN).
Immunohistology. Histology was performed as described previously 
(Espeli et al., 2011). Mouse spleens and kidneys were stained with the anti-
bodies described in Table S2 and mounted in Mowiol supplemented with 
DAPI. Staining was analyzed on an LSM510 confocal microscope with the 
LSM analysis software (Carl Zeiss) using a Plan-Neofluar 25× objective at 
room temperature for the spleen sections and a Plan-Apochromat 20× ob-
jective at 37°C for the kidney sections. Immune complex deposition in the 
kidney glomeruli was quantified using Volocity software (PerkinElmer). The 
relative intensity of IgG and IgM staining for each glomerulus was divided 
by the glomerulus area (in square micrometers).
Another striking feature of the FcRIIbwild/H1 KI mice is 
the transient production of autoantibodies after immuniza-
tion. Together with the age-related spontaneous autoanti-
body production, increased immune complex deposition in 
the renal glomeruli, and the enhanced severity of collagen-
induced arthritis observed in our KI mice, these findings 
demonstrate that naturally occurring variants of Fcgr2b can 
contribute to the development of autoimmune disease but, 
like all contributors to polygenic disease, need the additional 
influence of other genetic variants to achieve full disease pen-
etrance. These data provide insight into the mechanistic details 
of this contribution, suggesting that FcRIIb up-regulation 
plays a critical role in the counter-selection of autoreactive 
clones and contributes to the GC checkpoint long proposed 
to be important for maintaining peripheral tolerance (Goodnow 
et al., 1990; Nossal and Karvelas, 1990). The FcRIIb con-
tribution to that checkpoint appears to be to promote the 
apoptosis of bystander GC B cells by increasing the BCR 
threshold of activation, thus leading to the elimination of 
clones that could otherwise differentiate into autoreactive 
plasmablasts and/or memory B cells. The early onset of IgM 
autoantibodies after T-dependent and -independent immu-
nization may also suggest that FcRIIb up-regulation on 
activated B cells plays a role in the control of autoreactive 
plasmablasts before the GC reaction. Thus, FcRIIb may in-
fluence both affinity maturation and tolerance by controlling 
the survival of bystander B cells, a possibility which warrants 
confirmation in other models.
In summary, the study of a specific naturally occurring 
wild mouse promoter haplotype has directly implicated this 
variant in controlling GC formation, affinity maturation, and 
immunological tolerance and has also demonstrated the im-
portance of activation-induced up-regulation of the inhibitory 
FcRIIb in controlling immune responses and self-reactivity. 
It provides a definitive, controlled demonstration that a pro-
moter polymorphism that affects only stage-specific changes 
in the expression of a BCR signaling modulator is sufficient 
to contribute to autoimmunity.
MATERIALS AND METHODS
Mice and immunization. All experiments were performed according to 
the regulations of the UK Home Office Scientific Procedures Act (1986). 
The FcRIIbwild/H1 KI mice were generated at Ozgene (Köntgen et al., 
1993; Koentgen et al., 2010). A fragment of 1,271 bp from the NZB pro-
moter of FcRIIb was fused to 1,996 bp from the C57BL/6 promoter to 
form the 5 homology arm. The 3 homology arm was composed of 3,905 bp 
from the C57BL/6 promoter. Bruce 4 C57BL/6J ES cells were used to 
generate the FcRIIbwild/H1 KI mice. FcRIIbwild/H1 KI mice and WT litter-
mates were immunized with 100 µg NP-KLH (loading 27–29) or NP-Ficoll 
(loading 41; Biosearch Technologies) in alum (Thermo Fisher Scientific) in-
traperitoneally. When indicated, mice were immunized a second time 21 or 
27 d later with the same antigen.
Genetic analysis of Fcgr2b promoter polymorphisms. Genomic DNA 
was obtained from 53 strains of wild-caught mice or from wild mouse–
derived inbred strains from around the world (gift of F. Bonhomme [Institut 
des Sciences de l’Evolution-Montpellier, Montpellier, France] and J.-L. 
Guénet [Institut Pasteur, Paris, France]). The promoter was amplified using 
a nested PCR reaction using primers mGRII53(384) and mGRII35(87). 
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